HR and aneurysmal bone cyst: According to the phase III PALOMA-3 trial (NCT01942135), including patients with HR+/HER2− ABC whose disease had progressed after prior endocrine therapy (ET), the median PFS was 9.2 months for the fulvestrant plus palbociclib group compared to 3.8 months in the fulvestrant plus placebo group (HR 0.42, 95% CI 0.32–0.56; p < 0.001) [50,51].